Idioma:

Minocycline and Tigecycline: What Is Their Role in the Treatment of Carbapenem-Resistant Gram–Negative Organisms?

Shankar, Chaitra ; Nabarro, Laura E. B. ; Anandan, Shalini ; Veeraraghavan, Balaji

Microbial drug resistance (Larchmont, N.Y.), 2017-06, Vol.23 (4), p.437-446 [Periódico revisado por pares]

United States: Mary Ann Liebert, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Minocycline and Tigecycline: What Is Their Role in the Treatment of Carbapenem-Resistant Gram–Negative Organisms?
Autor: Shankar, Chaitra ; Nabarro, Laura E. B. ; Anandan, Shalini ; Veeraraghavan, Balaji
Assuntos: Acinetobacter baumannii - drug effects ; Acinetobacter baumannii - genetics ; Acinetobacter baumannii - isolation & purification ; Acinetobacter baumannii - metabolism ; Acinetobacter Infections - drug therapy ; Acinetobacter Infections - epidemiology ; Acinetobacter Infections - microbiology ; Anti-Bacterial Agents - pharmacology ; Antibiotics ; Bacteremia ; Bacterial infections ; Carbapenems ; Carbapenems - pharmacology ; Case-Control Studies ; Drug resistance ; Drug Resistance, Multiple, Bacterial - genetics ; Drug therapy ; Drugs ; Genes, MDR ; Gram-negative bacteria ; Humans ; In vivo methods and tests ; India - epidemiology ; Infections ; Klebsiella Infections - drug therapy ; Klebsiella Infections - epidemiology ; Klebsiella Infections - microbiology ; Klebsiella pneumoniae - drug effects ; Klebsiella pneumoniae - genetics ; Klebsiella pneumoniae - isolation & purification ; Klebsiella pneumoniae - metabolism ; Management ; Mechanisms ; Microbial Sensitivity Tests ; Minocycline ; Minocycline - analogs & derivatives ; Minocycline - pharmacology ; Mortality ; Organisms ; Patients ; Polymyxins ; Tigecycline
É parte de: Microbial drug resistance (Larchmont, N.Y.), 2017-06, Vol.23 (4), p.437-446
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Carbapenem-resistant organisms are increasingly common worldwide, particularly in India and are associated with high mortality rates especially in patients with severe infection such as bacteremia. Existing drugs such as carbapenems and polymyxins have a number of disadvantages, but remain the mainstay of treatment. The tetracycline class of antibiotics was first produced in the 1940s. Minocycline, tetracycline derivative, although licensed for treatment of wide range of infections, has not been considered for treatment of multidrug-resistant organisms until recently and needs further in vivo studies. Tigecycline, a derivative of minocycline, although with certain disadvantages, has been frequently used in the treatment of carbapenem-resistant organisms. In this article, we review the properties of minocycline and tigecycline, the common mechanisms of resistance, and assess their role in the management of carbapenem-resistant organisms.
Editor: United States: Mary Ann Liebert, Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Minocycline and Tigecycline: What Is Their Role in the Treatment of Carbapenem-Resistant Gram–Negative Organisms?

Shankar, Chaitra ; Nabarro, Laura E. B. ; Anandan, Shalini ; Veeraraghavan, Balaji

United States: Mary Ann Liebert, Inc

Buscando em bases de dados remotas. Favor aguardar.